Skip to main content
. 2020 Aug 11;9(19):7052–7061. doi: 10.1002/cam4.3378

FIGURE 1.

FIGURE 1

Kaplan‐Meier analysis for overall survival of patients with different severity of hepatic adverse events during the use of immune checkpoint inhibitors (grade 0 vs grade 1‐2 vs grade 3‐4): A, all patients (log‐rank test, P < .001); B, lung cancer (log‐rank test, P = .001); C, gastrointestinal cancer (log‐rank test, P = .023), D, liver cancer (log‐rank test, P < .001), E, hematological cancer (log‐rank test, P = .023)